Learn More
BACKGROUND Reductions in the dose intensity (DI) of adjuvant anthracycline-based chemotherapy in early stage breast cancer are frequently required due to treatment toxicity or poor tolerance, but the implications of a minimal reduction in DI on clinical outcome remain uncertain. PATIENTS AND METHODS Women with stage I-II breast cancer treated with(More)
BACKGROUND The BC Cancer Agency Gastro-intestinal Tumor Group supports one standard of care (SOC) chemotherapy regimen for metastatic esophagogastric adenocarcinoma-specifically, weekly cisplatin and 5-fluorouracil (5FU) infusion. All other regimens require Compassionate Access Program (CAP) approval for public funding. OBJECTIVES We examined response,(More)
In this study, we set out to determine the frequency and severity of anemia and the corrective interventions used during adjuvant chemotherapy for breast cancer.We conducted a retrospective electronic chart review of 702 patients who received adjuvant breast cancer chemotherapy at four BC Cancer Agency centres in 2002 and 2003. For these patients, we(More)
Relatively little is known about the risk of residual neurological deficit following partial complex status epilepticus (PCSE). To address this issue, we administered serial neuropsychological assessments and EEGs to a young cocaine abuser following the resolution of an extended episode of PCSE. Results suggest that PCSE may be associated with prolonged but(More)
  • 1